title: Use of animal model of sepsis to evaluate novel herbal therapies.
abstract: Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial infection. It has been routinely simulated in animals by several techniques, including infusion of exogenous bacterial toxin (endotoxemia) or bacteria (bacteremia), as well as surgical perforation of the cecum by cecal ligation and puncture (CLP). CLP allows bacteria spillage and fecal contamination of the peritoneal cavity, mimicking the human clinical disease of perforated appendicitis or diverticulitis. The severity of sepsis, as reflected by the eventual mortality rates, can be controlled surgically by varying the size of the needle used for cecal puncture. In animals, CLP induces similar, biphasic hemodynamic cardiovascular, metabolic, and immunological responses as observed during the clinical course of human sepsis. Thus, the CLP model is considered as one of the most clinically relevant models for experimental sepsis. Various animal models have been used to elucidate the intricate mechanisms underlying the pathogenesis of experimental sepsis. The lethal consequence of sepsis is attributable partly to an excessive accumulation of early cytokines (such as TNF, IL-1 and IFN-γ) and late proinflammatory mediators (e.g., HMGB1). Compared with early proinflammatory cytokines, late-acting mediators have a wider therapeutic window for clinical applications. For instance, delayed administration of HMGB1-neutralizing antibodies beginning 24 hours after CLP, still rescued mice from lethality, establishing HMGB1 as a late mediator of lethal sepsis. The discovery of HMGB1 as a late-acting mediator has initiated a new field of investigation for the development of sepsis therapies using Traditional Chinese Herbal Medicine. In this paper, we describe a procedure of CLP-induced sepsis, and its usage in screening herbal medicine for HMGB1-targeting therapies.
authors.affiliation: The Feinstein Institute for Medical Research, North Shore-LIJ Health System, NY, USA.
authors.forename: Wei
authors.initials: W
authors.lastname: Li
authors.forename: Shu
authors.initials: S
authors.lastname: Zhu
authors.forename: Yusong
authors.initials: Y
authors.lastname: Zhang
authors.forename: Jianhua
authors.initials: J
authors.lastname: Li
authors.forename: Andrew E
authors.initials: AE
authors.lastname: Sama
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
authors.forename: Haichao
authors.initials: H
authors.lastname: Wang
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D024243:HMGB1 Protein / Q000037:antagonists & inhibitors; D051379:Mice; D058990:Molecular Targeted Therapy; D028321:Plant Preparations / Q000494:pharmacology*; D018805:Sepsis / Q000188:drug therapy*
chemical_list: D024243:HMGB1 Protein; D028321:Plant Preparations